148 related articles for article (PubMed ID: 32061548)
1. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.
Hoffman-Censits J; Choi W; Pal S; Trabulsi E; Kelly WK; Hahn NM; McConkey D; Comperat E; Matoso A; Cussenot O; Cancel-Tassin G; Fong MHY; Ross J; Madison R; Ali S
Eur Urol Oncol; 2021 Apr; 4(2):297-300. PubMed ID: 32061548
[TBL] [Abstract][Full Text] [Related]
2. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes.
Burgess EF; Sanders JA; Livasy C; Symanowski J; Gatalica Z; Steuerwald NM; Arguello D; Brouwer CR; Korn WM; Grigg CM; Zhu J; Matulay JT; Clark PE; Heath EI; Raghavan D
Urol Oncol; 2022 Aug; 40(8):383.e1-383.e10. PubMed ID: 35662501
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
[TBL] [Abstract][Full Text] [Related]
5. Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma.
De Lorenzis E; Albo G; Longo F; Bebi C; Boeri L; Montanari E
Genes (Basel); 2021 Feb; 12(3):. PubMed ID: 33668859
[TBL] [Abstract][Full Text] [Related]
6. Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladder.
Parimi V; Choi W; Feng M; Fong M; Hoffman-Censits J; Kates M; Lombardo KA; Comperat E; McConkey DJ; Hahn NM; Esteves RS; Matoso A
Histopathology; 2023 Jun; 82(7):991-1002. PubMed ID: 36754853
[TBL] [Abstract][Full Text] [Related]
7. Genomic Characterization of Upper Tract Urothelial Carcinoma.
Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
[TBL] [Abstract][Full Text] [Related]
8. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
10. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
11. Evaluation of molecular signatures in the urinary bladder and upper tract urothelial carcinomas: a prospective controlled clinical study.
Dawood EE; Awadalla A; Hashem A; Shokeir AA; Abdel-Aziz AF
J Egypt Natl Canc Inst; 2022 Nov; 34(1):47. PubMed ID: 36372809
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.
Koshkin VS; Garcia JA; Reynolds J; Elson P; Magi-Galluzzi C; McKenney JK; Isse K; Bishop E; Saunders LR; Balyimez A; Rashid S; Hu M; Stephenson AJ; Fergany AF; Lee BH; Haber GP; Dowlati A; Gilligan T; Ornstein MC; Rini BI; Abazeed ME; Mian OY; Grivas P
Clin Cancer Res; 2019 Jan; 25(1):210-221. PubMed ID: 30327311
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
Posada JM; Yakirevich E; Kamat AM; Sood A; Jacob JM; Bratslavsky G; Grivas P; Spiess PE; Li R; Necchi A; Mega AE; Golijanin DJ; Pavlick D; Huang RSP; Lin D; Danziger N; Sokol ES; Sivakumar S; Ross JS; Cheng L
Mod Pathol; 2024 Mar; 37(3):100424. PubMed ID: 38219954
[TBL] [Abstract][Full Text] [Related]
14. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
[TBL] [Abstract][Full Text] [Related]
16. Differences in genomic profile of high-grade urothelial carcinoma according to tumor location.
Park CK; Cho NH
Urol Oncol; 2022 Mar; 40(3):109.e1-109.e9. PubMed ID: 34663543
[TBL] [Abstract][Full Text] [Related]
17. Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis.
Chang MT; Penson A; Desai NB; Socci ND; Shen R; Seshan VE; Kundra R; Abeshouse A; Viale A; Cha EK; Hao X; Reuter VE; Rudin CM; Bochner BH; Rosenberg JE; Bajorin DF; Schultz N; Berger MF; Iyer G; Solit DB; Al-Ahmadie HA; Taylor BS
Clin Cancer Res; 2018 Apr; 24(8):1965-1973. PubMed ID: 29180607
[No Abstract] [Full Text] [Related]
18. Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.
Sjödahl G; Eriksson P; Patschan O; Marzouka NA; Jakobsson L; Bernardo C; Lövgren K; Chebil G; Zwarthoff E; Liedberg F; Höglund M
Int J Cancer; 2020 May; 146(9):2636-2647. PubMed ID: 31609466
[TBL] [Abstract][Full Text] [Related]
19. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
20. POU2F3-positive small cell carcinoma of the bladder: A clinicopathologic analysis of 4 cases and literature review.
Cai Z; Cheng X; Liao S; Zou W; Li L; Liu F; Huang W
Pathol Res Pract; 2024 May; 257():155296. PubMed ID: 38615507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
